Annette S. Little
Horizon Discovery Group (United Kingdom)(GB)
Publications by Year
Research Areas
CRISPR and Genetic Engineering, Melanoma and MAPK Pathways, Advanced biosensing and bioanalysis techniques, Virus-based gene therapy research, Cancer Cells and Metastasis
Most-Cited Works
- → Amplification of the Driving Oncogene, KRAS or BRAF , Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells(2011)205 cited
- → Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance(2012)141 cited
- → Mechanisms of acquired resistance to ERK1/2 pathway inhibitors(2012)110 cited
- → Dual direction CRISPR transcriptional regulation screening uncovers gene networks driving drug resistance(2017)61 cited
- → Increasing the performance of pooled CRISPR–Cas9 drop-out screening(2016)44 cited
- → A Correction to the Research Article Titled: “Amplification of the Driving Oncogene, KRAS or BRAF , Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells” by A. S. Little, K. Balmanno, M. J. Sale, S. Newman, J. R. Dry, M. Hampson, P. A. W. Edwards, P. D. Smith, S. J. Cook(2011)44 cited
- → Identification of approved and investigational drugs that inhibit hypoxia-inducible factor-1 signaling(2016)27 cited
- → Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling(2012)23 cited
- → 193 Generation of Novel Reporter Cell Lines Facilitating the Measurement of Endogenous Gene Expression(2012)
- → Abstract A148: Modeling patient responses to targeted therapy with rAAV mediated gene editing.(2013)